At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09939 KINTOR PHARMA-B
Not Yet Opened 08-27 16:08:29
1.665
-0.025
-1.48%
High1.740
Low1.600
Vol2.24M
Open1.730
D1 Closing1.690
Amplitude8.28%
Mkt Cap830.84M
Tradable Cap830.84M
Total Shares499.00M
T/O3.68M
T/O Rate0.45%
Tradable Shares499.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
TYK MEDICINES-B Secures Conditional NMPA Approval for Its Novel EGFR-TKI Therapy
ACFTU Launches Second National Team Leader Competition With Ten Industry Tracks Including Rail, Power, Pharma, Machinery, Metallurgy, Building Materials, Defense Tech, ICT, Light Industry, and Textiles
ETF Market Daily: Healthcare Sector Shows Solid Valuations While Innovative Drug Subsegments See Dense Catalysts, Spotlight on Hang Seng Biotech ETF and STAR Innovative Drug ETF
Hong Kong Stock Alert | ALEBUND-B (09637) Surges Over 6% on Dual Catalysts of Index Inclusion and Earnings, with Mircera Commercialization Poised for Growth
Innovative Drugs Suddenly Lose Steam: What's Behind the Pullback? Chinese Fund Flags Technical Support Breach as CXO Leaders Slump, Yet Q4 Outlook for Healthcare Stays Bullish
Kintor Pharmaceutical Ltd is an investment holding company primarily engaged in the research and development of innovative medicine products. The Company's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers indications of dermatology (such as androgenetic alopecia, acne vulgaris) and indications of tumors. The Company has two core drugs in the dermatology field, KX-826 and GT20029. The Company's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.